- Botswana, Cape Verde, Eritrea, Namibia, Rwanda, São Tomé and Príncipe, South Africa, and Swaziland for achieving the Millennium Development Goals (MDGs) target for malaria
- Rwanda, Senegal and Liberia for Performance in Malaria Control between 2011 and 2015
- Mali, Guinea and Comoros for being the Most Improved in Malaria Control between 2011 and 2015
Support MalariaWorld to provide Open Access to malaria information for all. We will use your donation solely to further develop MalariaWorld. MalariaWorld is a project of the Dutch Malaria Foundation, a charitable, registered, not-for-profit organisation. If you still have any questions then just contact us at email@example.com
MalariaWorld Journal (MWJ) is the only peer-reviewed Open Access journal on malaria where you don’t pay to publish, you don’t pay to read, and authors get paid € 150 for each published paper. Read about MW and how you can submit your manuscript here.
Log in at MalariaWorld. Remember that you have to log-in at MW to read more, respond to polls, open attachments and get free copies of books and other documents. Forgot your username and/or password? Go to www.malariaworld.org, click on Sign in and then on Request new password. Fill out your email address that you use to receive the MW newsletter and the Word verification. You will then receive further instructions by email.
BBC NEWS | Health, 24 July 2015
By: Fergus Walsh, Medical correspondent
Introducing rapid diagnostic tests in Ugandan drug shops improves treatment of malaria patients
Using malaria rapid diagnostic tests (RDT) in registered drug shops in a highly endemic region in Uganda substantially reduced overdiagnosis of malaria, improving the use of valuable malaria drugs, according to a new study published in PLOS ONE.
Help us to win the Social Media 'Malaria Heroes' Award 2015
Candidate vaccines based on injectable Plasmodium falciparum (Pf) sporozoites (SPZ), are being developed and tested. These include PfSPZ Vaccine, in which the PfSPZ are attenuated by irradiation; PfSPZ-CVac, in which fully infectious PfSPZ, PfSPZ Challenge, are attenuated in vivo by an anti-malarial drug, to allow only liver stage parasites to grow, and PfSPZ-GA1, in which the PfSPZ are attenuated by gene deletions.